The FDA has approved Lumipulse, the first blood test for Alzheimer's diagnosis in symptomatic older adults, enabling less invasive detection of amyloid plaques and supporting earlier, accurate diagnosis and treatment options.

Insights on recent shifts in U.S. health policy: autism research, drug pricing reforms, HHS operational cuts, abortion access, and legal challenges to insurance preventive care coverage.

Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.

President Trump's executive order prompts potential changes in Medicare drug price negotiation, affecting pharmaceutical pricing, Medicare spending, and FDA drug import regulations. Epic Systems also shifts to a more public presence in healthcare IT.

Major staff and budget cuts at key U.S. public health agencies like CDC and FDA risk weakening national health infrastructure and crisis preparedness.

The Health Tech Investment Act aims to create a consistent Medicare payment system for FDA-approved AI medical devices, enhancing patient access and improving healthcare outcomes.

Robert F. Kennedy Jr. announces a major workforce reduction at HHS, aiming to streamline operations and save $1.8 billion amid a focus on public health.

Explore the FDA's potential authority to regulate health insurance coverage algorithms and their implications for patient care.